title: Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL).
abstract: Inhibitor of apoptosis protein (IAP)-family proteins suppress apoptotic signaling in normal/neoplastic cells in various settings. To determine the apoptosis-resistant mechanism in adult acute mixed lineage leukemia (AMLL) with biphenotypic blasts responsible for resistance against chemotherapy, the expression levels of IAP-family proteins in AMLL bone marrow cells were analyzed by quantitative RT-PCR. The overall expression levels of IAPs were higher than those in control, AML, and ALL cells. A significant difference for the expression of survivin was observed between AMLL and AML (P <0.05), and differences between AMLL and ALL were significant for the expression of survivin (P <0.05), NAIP (P <0.05), and XIAP (P <0.05). These findings suggest that higher expression of various IAPs is associated with the chemotherapy-resistant nature of this specific type of leukemia.
authors.affiliation: Department of Comprehensive Pathology, Aging and Developmental Sciences, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Maki
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Morito
authors.initials: M
authors.lastname: Kurata
authors.forename: Kouhei
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Shinya
authors.initials: S
authors.lastname: Abe
authors.forename: Miori
authors.initials: M
authors.lastname: Inoue
authors.forename: Tamiko
authors.initials: T
authors.lastname: Takemura
authors.forename: Katsuiku
authors.initials: K
authors.lastname: Hirokawa
authors.forename: Kenshi
authors.initials: K
authors.lastname: Suzuki
authors.forename: Masanobu
authors.initials: M
authors.lastname: Kitagawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism*; D001854:Bone Marrow Cells / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D051034:Inhibitor of Apoptosis Proteins; D015456:Leukemia, Biphenotypic, Acute / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008297:Male; D008869:Microtubule-Associated Proteins / Q000032:analysis / Q000378:metabolism; D008875:Middle Aged; D009363:Neoplasm Proteins; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011506:Proteins / Q000032:analysis / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D011506:Proteins; D012333:RNA, Messenger; D000077022:Survivin